Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of VK2735 in Healthy and Overweight/Obese Adults
NCT05203237Phase 1Completed
- Sponsor
- Viking Therapeutics
- Start
- Dec 2021
- Primary completion
- Nov 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VK-2735 in obesity and Overweight (6 arms), sponsored by Viking Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs) at 8 days. Started Dec 2021; status: completed.
02
Drugs
VK-2735
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05203237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203237.